DJIA 16,934.77 22.48 0.13%
NASDAQ 4,758.38 -32.77 -0.68%
S&P 500 1,995.40 -0.43 -0.02%
market minute promo

Galena Biopharma, Inc. (NASDAQ: GALE)

1.72 -0.04 (-2.27%)

Quote as of

company name or ticker

Recent Quotes

GALE $1.72 -2.27%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.76
Previous Close $1.76
Daily Range $1.69 - $1.76
52-Week Range $1.10 - $2.39
Market Cap $278.2M
P/E Ratio -5.87
Dividend (Yield) $0.00 (0.0%)
Volume 425,781
Average Daily Volume 1,584,717
Current FY EPS -$0.32




Drug Makers

Galena Biopharma, Inc. (GALE) Description

Galena Biopharma Inc is a biotechnology company focused on discovering developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. Website:

News & Commentary

Cancer Immunotherapy Developer Galena Biopharma Can't Win for Trying

Based on its share price, you'd think Galena's clinical pipeline hit a brick wall, but that just isn't the case.

Galena Biopharma Just Surged 14% -- Here's Why

Galena Biopharma lands a new collaborate partner and explodes higher by double-digits. Is this move sustainable?

Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With Ne

Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients

3 Small-Cap Biotech Stocks Crushing Shareholder Value With Stock Offerings

Issuing stock is way of life for some small-cap biotech companies looking to raise cash. However, these three in particular are notorious for diluting shareholder value.

3 Dangerous Biotech Stocks

Biotech stocks are risky by nature, but as they exist on a spectrum, some are higher risk than average. Which biotech stocks do our contributors think investors should avoid?

5 Things Galena Biopharma Wants You to Know

Galena may have delivered the dreaded double miss in the second quarter, but there's much more to this biotech company than meets the eye.

Why Galena Biopharma Jumped 10% Today

Independent monitors are reducing cardiac monitoring in a key Galena Biopharma phase 3 trials.

Ocata Therapeutics: Insider Enrichment, Failed Science, Long History Of Fraud Ties, 77% Downside

Galena Biopharma Comes Up Short in Q2 and Investors Pounce

Galena's earnings results miss the mark once again, but does the promise of its pipeline make this stock a buy?

Galena Biopharma's (GALE) CEO Mark Schwartz on Q2 2015 Results - Earnings Call Transcript

See More GALE News...

GALE's Top Competitors

GALE $1.72 (-2.27%)
Current stock: GALE
AMGN $148.78 (0.49%)
Current stock: AMGN
GILD $99.15 (-1.12%)
Current stock: GILD
BIIB $276.86 (-0.85%)
Current stock: BIIB